RT Journal Article
SR Electronic
T1 Somatostatin, gastrointestinal peptides, and the carcinoid syndrome.
JF Gut
JO Gut
FD BMJ Publishing Group Ltd and British Society of Gastroenterology
SP 549
OP 553
DO 10.1136/gut.22.7.549
VO 22
IS 7
A1 R G Long
A1 J R Peters
A1 S R Bloom
A1 M R Brown
A1 W Vale
A1 J E Rivier
A1 D G Grahame-Smith
YR 1981
UL http://gut.bmj.com/content/22/7/549.abstract
AB During a control infusion noradrenaline and alcohol each provoked carcinoid flushing in four of five patients and pentagastrin in two of five patients. When tetradecapeptide somatostatin was infused on another day no patient flushed at any time, even when 16 microgram of either noradrenaline or pentagastrin were administered. Carcinoid flushing was not associated with release of gastrin or any of the other vasoactive or postprandially released gut regulatory peptides measured. In a sixth patient with severe prolonged carcinoid flushing, subcutaneous Des AA1, 2, 4, 5, 12D Trp8 somatostatin markedly reduced the incidence and severity of flushing for two days. Somatostatin is thus a potent inhibitor of carcinoid flushing, but no evidence has been found for the gut hormones measured to be mediators of flushing.